Full Breakdown
Kodiak Sciences Reports Positive Phase 3 DAYBREAK Results for Wet-AMD Therapies
By Drooid · · How we work
Core Event: DAYBREAK Trial Demonstrates Non-Inferior Vision Gains
- On Monday, Kodiak Sciences Inc. released topline data from its Phase 3 DAYBREAK study evaluating two investigational drugs, Zenkuda (tarcocimab tedromer) and tabirafusp-alfa tedromer (KSI-501), in treatment-naïve patients with wet age-related macular degeneration (wAMD).
- Both agents met the primary vision-gain endpoint by showing non-inferior improvement to aflibercept (Regeneron’s Eylea) after one year.
- Zenkuda achieved a p-value of 0.0007; tabirafusp-ted recorded a p-value of 0.0036 for the primary endpoint and a key anatomical secondary endpoint with p < 0.0001.
Background & Context: Unmet Need for Longer-Acting Anti-VEGF Therapies
- Wet AMD is currently managed with anti-VEGF injections such as aflibercept, faricimab (Vabysmo) and Eylea, typically administered every four to eight weeks.
- Frequent intravitreal injections create logistical burdens for patients, many of whom face mobility or transportation challenges.
- Kodiak’s Antibody Biopolymer Conjugate (ABC) platform is designed to extend intra-ocular drug half-life, targeting dosing intervals of up to six months.
Data & Statistics
- Dosing interval: 54 % of Zenkuda-treated participants reached a six-month (24-week) interval under a treat-to-dryness retreatment algorithm.
- Vision gains: Zenkuda improved visual acuity by 7.2 letters on average versus 7.6 letters for aflibercept; tabirafusp-ted improved by 6.3 letters, both meeting non-inferiority criteria.
- Safety: Zenkuda showed 0 % intra-ocular inflammation and a 0.5 % cataract adverse-event rate, compared with 0.9 % cataract rate for aflibercept. Tabirafusp-ted reported 0.4 % intra-ocular inflammation and no cataract events.
- Study size: 690 treatment-naïve wAMD patients were randomized equally to Zenkuda, tabirafusp-ted, or aflibercept.
Official Statements & Responses
- The company also noted parallel advancement of tabirafusp-ted in a Phase 3 ALTO study for diabetic macular edema, enrolling roughly 910 patients worldwide.
Verbatim Quotes
- “Today’s results are deeply satisfying. Four years and seven months after our first Phase III readout, Zenkuda’s profile has come fully into focus,” — J. Pablo Velazquez-Martin, MD, chief medical officer at Kodiak, in a press statement
What’s Next: Regulatory Pathway and Market Outlook
- Kodiak plans to submit a three-indication BLA for Zenkuda in the fourth quarter of 2026, leveraging data from five successful Phase 3 trials (DAYBREAK, DAYLIGHT, GLOW1, GLOW2, BEACON).
- Additional topline data for the KSI-101 candidate are expected in December 2026, with a second Phase 3 readout slated for early 2027.
- The anti-VEGF market, valued at roughly $26 billion in 2024, includes a $15 billion segment for retinal vascular diseases; the FDA’s approval of LYTENAVA (bevacizumab-vikg) on July 24, 2026 adds another competitor in this space.
- Kodiak will host a webcast on September 28 to discuss the DAYBREAK data with investors and clinicians.
Market Reaction
- Following the announcement, Kodiak’s shares surged more than 150 % in early trading, reaching a near-five-year high of $89.92 per share.
- Baker Bros., the largest shareholder, holds roughly 30 % of the company’s outstanding equity.